Pharmaron Beijing Co., Ltd.
Research Pharmaron Beijing Co., Ltd. (3759.HK) on Bullrun: market cap HKD 48.50B, P/E 25.6, dividend yield 0.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3759.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 48.50B
- P/E25.6
- Dividend yield0.8%
- Financial periodQ2 2026
- RevenueCNY 4.02B
- Net incomeCNY 414.83M
- Free cash flow-CNY 308.98M
- Gross margin32.9%
Valuation Snapshot
latest market cap is HKD 48.50B; P/E is 25.6; dividend yield is 0.8%.
Peer valuation comparison
Latest P/E is 25.63x versus a Healthcare sector median of 21.8x (17.6% above).
Latest dividend yield is 0.77% versus a Healthcare sector median of 2.4% (67.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 48.50B | 25.6 | 0.9% | 0.23 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.23 HKD, yield 0.8%.
About Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others.
ETFs that hold Pharmaron Beijing Co., Ltd.
US-listed ETFs
Pharmaron Beijing Co., Ltd. is held by 22 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Schwab Emerging Markets Equity ETF (SCHE) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | 0.01% | 0.39% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharmaron Beijing Co., Ltd.'s market cap?
Pharmaron Beijing Co., Ltd.'s market capitalization is HKD 48.50B.
What is Pharmaron Beijing Co., Ltd.'s P/E ratio?
Pharmaron Beijing Co., Ltd.'s price-to-earnings (P/E) ratio is 25.6.
Does Pharmaron Beijing Co., Ltd. pay a dividend?
Pharmaron Beijing Co., Ltd. has a dividend yield of 0.8%.
What does Pharmaron Beijing Co., Ltd. do?
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others.